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In this issue of SQUMJ, Yadav et al. present a very interesting article about opportunistic infections and complications in 
children infected with human immunodeficiency 
virus (HIV)-1.1 It is well known that both HIV-
1 and HIV-2 progressively destroy lymphocytes, 
rendering the patient susceptible to a variety of 
other infectious agents; these infections are known 
as opportunistic infections.2 At least 90% of HIV-
infected children acquire the infection from their 
mothers through mother-to-child transmission 
(MTCT).2 Approximately half of these cases occur 
late in pregnancy, possibly in the days before the 
delivery, as the placenta begins to separate from the 
uterine wall.3 Only a small proportion of cases (<4%) 
seem to occur in the first trimester, less than 20% by 
36 weeks of gestation and approximately one-third 
during delivery.3 Many factors may increase the 
transplacental transmission of the virus to the fetus 
in utero, such as an increased plasma viral load; this 
also exposes the baby to increased concentrations of 
the virus in the female genital tract during childbirth. 
Maternal sexually transmitted diseases, Epstein-Barr 
virus infection, viral shedding, vaginal candidiasis 
and cervical inflammation are known risk factors for 
the MTCT of HIV.4 The risk of HIV transmission 
is also higher in cases of prolonged rupture of the 
amniotic membranes before delivery,3 which is usually 
associated with acute and chronic inflammation of 
the placental membranes.5 In spite of its importance 
in terms of other health benefits, breastfeeding 
unfortunately puts the infant at risk of acquiring HIV 
throughout the entire breastfeeding period, even 
if the infant is initially uninfected. In the absence of 
preventive interventions, about 5−20% of infants with 
HIV-positive mothers become infected through the 
process of breastfeeding.6
There is assuredly a potential benefit to testing 
infants for HIV infection soon after birth, i.e. before 
the infant is 48 hours old, so as to quickly identify 
infants infected in utero and prevent early mortality.7 
However, certain rapid diagnostic tests, such as the 
current available HIV serological assays, cannot be 
used for diagnosis in infants below 18 months of age. 
This is due to the presence of maternal HIV antibodies,8 
although these usually clear by 9−12 months.6 While 
these tests can undoubtedly be used to screen for HIV 
exposure among children >18 months old, a definitive 
diagnosis of HIV infection can only be confirmed 
with virological testing.9 In this regard, the Panel on 
Antiretroviral Therapy and Medical Management of 
HIV-Infected Children recommended two assays for 
virological detection: the HIV ribonucleic acid (RNA) 
and HIV branched deoxyribonucleic acid (bDNA) 
polymerase chain reaction (PCR) assays.10 Between 
the two, the latter is usually less expensive.11 Further 
virological testing in infants with known perinatal 
HIV exposure is recommended when the infant is 14 
days, one month and four months old.11 Testing when 
the infant is 14 days old allows for the earlier detection 
of HIV in infants who have had negative test results 
within the first 48 hours of life. At the age of one 
month old, testing confirms the previous results, as 
PCR testing has a 96% sensitivity and 99% specificity 
for identifying HIV at this age.11 Once HIV infection 
has been diagnosed, the course of the infection 
must be frequently monitored by determining the 
number of cluster of differentiation 4 positive (CD4+) 
lymphocytes (otherwise known as the CD4+ count, 
which decreases as the infection worsens) and the 
number of virus particles in the blood (also termed the 
viral load, which increases as the infection worsens).2
Children born with HIV infections rarely display 
symptoms in the first few months of life. Even without 
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treatment, approximately 80% of infected children 
do not develop problems during their first or second 
year.2 For the remaining children, problems may 
not appear until the age of three years or later.2 The 
rate of progression to a stage of clinically apparent 
immunosuppression depends on maternal, infant 
and viral factors.12 Once this occurs, HIV/acquired 
immunodeficiency syndrome (AIDS) will negatively 
affect the children’s health, education and well-being. 
Early signs of infection include delayed growth and 
recurring bacterial infections.2 In a significant number 
of HIV-infected children, progressive brain damage 
prevents or delays developmental milestones, such 
as walking and talking. These children may also have 
impaired intelligence and a small head in relation to 
their body size.2 Up to 20% of infected children who are 
left untreated progressively lose social and language 
skills as well as muscle control.2
The initiation of antiretroviral therapy (ART) in 
infants and children should be based on age, CD4+ 
count and clinical stage. An infected infant aged 
one year or older suffering from AIDS or showing 
significant symptoms of the disease should be 
immediately treated, regardless of the results of CD4+ 
percentage and count or virological assays.11 For 
children, the drugs used during treatment are more 
or less the same as those used for adults—typically a 
combination of two nucleoside or nucleotide reverse 
transcriptase inhibitors (NRTIs) plus one non-
nucleoside reverse transcriptase inhibitor (NNRTI) 
or one protease inhibitor (PI).11 The effectiveness 
of the treatment should be monitored by regularly 
measuring the viral load in the blood and the CD4+ 
count.2 Yadav et al. observed that the severity and 
frequency of opportunistic complications in paediatric 
patients infected with HIV-1 increased with a fall in the 
CD4+ count.1 The authors hypothesised that treating 
the opportunistic infections, along with ART, might 
lead to both clinical and immunological recovery 
and a decreased incidence of future opportunistic 
infections.1 While opportunistic infections in adults are 
secondary to the reactivation of opportunistic pathogens 
acquired when the host’s immune system was still 
intact, opportunistic infections in children usually 
reflect a primary infection.4 Among children with 
perinatal HIV infection, the primary opportunistic 
infection occurs after HIV infection is established 
and the child’s immune system has already been 
compromised. This can lead to different disease 
manifestations than those witnessed among adult 
patients.4
In general, HIV treatment should continue 
indefinitely, or at least until the child is five years old, 
though it may sometimes be stopped following the 
successful completion of ART.13 It is important to 
mention here that treating infected children is not 
an easy task. Some of the drugs used to treat adult 
patients, which are not in liquid form, are not suitable 
for infants and young children. Complicated drug 
regimens can also limit the effectiveness of chosen 
therapies as they may be difficult to follow for both 
parents and children in the long term.2 Additionally, 
the side-effects of certain drugs, though better 
tolerated by children in comparison to adults, may also 
limit the treatment of HIV-infected children.2 
Current advances in HIV treatment are changing 
the pattern of HIV/AIDS in clinical settings. Prior 
to effective antiviral suppressive therapies, the 
majority of HIV-infected infants developed marked 
immunosuppression and AIDS-defining conditions at 
an early age. Today, ART makes it possible for children 
to experience prolonged viral suppression and live 
well into their adolescence and early adulthood.14 
The prognosis is worse for those in whom the virus is 
detected within the first week of life or for those who 
develop symptoms in the first year of life.2
The latest report by the United Nations Children’s 
Fund explores the strides that have been made in the 
fight against HIV.15 In this report, more than 850,000 
children in low- and middle-income countries, whose 
mothers were living with HIV, were estimated to have 
been born without contracting the infection between 
2005 and 2012.15 However, despite the progress 
achieved, there is still a long way to go—in 2012, 
around 260,000 children in low- and middle-income 
countries were newly infected with HIV and during 
that year almost 600 children died from AIDS-related 
causes every day.16 As stated by Yadav et al., HIV 
infection is rapidly increasing among the paediatric 
HIV population in India and, with the current rate 
of increase, India will soon have the highest AIDS 
prevalence worldwide.1
In the Middle Eastern and North African (MENA) 
region, the HIV epidemic has been rising since 2001. 
This region is currently among the top two regions 
(along with sub-Saharan Africa) in the world with 
the fastest growing HIV epidemics.17 The number 
of children younger than 15 years living with HIV 
and those newly infected with HIV in the region is 
increasing.17 Also, ART coverage in the region remains 
one of the lowest in the world. In 2010, the percentage 
of pregnant women receiving the most effective 
antiretroviral regimen for the prevention of MTCT 
was less than 5% and the percentage of infants exposed 
to HIV who received antiretroviral prophylaxis was 
only 2%.17 HIV-related stigma and discrimination are 
no doubt still rife in the MENA region and these are 
major barriers to the utilisation of HIV-preventive 
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services. Accordingly, the use of counselling and 
testing services is generally low; it may be even lower 
for women, given the prevailing cultures and traditions 
of this region.17 Moreover, women with an increased 
risk of contracting HIV suffer from a lack of services 
that are adapted to their needs. There is an inadequate 
understanding of the vulnerability of women who do 
not themselves engage in high-risk behaviours but 
are nevertheless exposed to HIV infections.17 One 
encouraging sign in the MENA region is in the case of 
Oman, a nation which has demonstrated an acceptance 
of HIV-specific screening interventions despite the 
inherent cultural sensitivities of this topic. In 2009, 
Oman offered HIV testing to all women attending 
antenatal care clinics, with 99% of them opting for the 
test.17 Furthermore, the percentage of ART coverage 
recorded in Oman was the highest in the region (78%), 
followed by Morocco (26%).17 
In recent years, the global efforts expended to 
combat HIV/AIDS have increased, with an accelerated 
global commitment to the prevention of MTCT. 
For instance, the Joint United Nations Programme 
on HIV/AIDS (UNAIDS) and the World Health 
Organization (WHO) introduced a new initiative in 
June 2010 aiming to achieve and sustain universal 
access to ART and maximise the benefits of different 
HIV-preventive interventions through focused work 
in five priority areas.18 One important priority area 
is to provide HIV testing nearer to the point-of-care 
(POC).18 This is particularly important because new 
innovations such as simplified virological testing make 
it possible to provide an earlier diagnosis for infants 
closer to the POC and facilitate the introduction of 
rapid and integrated treatment. 
In 2011, the United Nations hosted a High-Level 
Meeting on AIDS in New York, in which the General 
Assembly adopted the Political Declaration on HIV/
AIDS.19 One of the targets of this declaration was to 
eliminate the MTCT of HIV by 2015.20 In this instance, 
elimination is defined as a 90% reduction in the 
number of new paediatric HIV infections, or a MTCT 
rate of below 5%.20 All nations will have to show great 
dedication to achieving this target as the deadline 
approaches. The WHO validation requirements for 
this elimination are based on documented evidence on 
the achievement of the elimination targets for at least 
three consecutive years, the existence of an adequate 
surveillance system and evidence of each programme’s 
capacity to sustain the elimination targets and 
objectives in the future.17 
Crucially, sustained national commitment, 
sufficient human and financial resources and the 
delivery of critical interventions are key points for 
the success of any programme aiming to eliminate 
the MTCT of HIV. Interventions should focus on 
simplifying and enhancing accessibility to treatment 
and other services for pregnant women living with HIV 
and on relieving the suffering of those most afflicted by 
the epidemic. With all these factors in hand, an HIV/
AIDS-free generation may well be within reach and 
will be a strong foundation for a better future. 
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